Catalog No.
YHE11401
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Ala28-Trp306
Predicted molecular weight
34.09 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P35475
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
IDUA, Alpha-L-iduronidase
Combining clinically benign IDUA variants in cis reduces enzymatic activity of the resulting enzyme within the pathogenic range., PMID:40359731
Genetic variations in the IDUA gene in Tunisian MPS I families: Identification of a novel microdeletion disrupting substrate binding and structural insights., PMID:40291162
N-glycan-modified α-L-iduronidase produced by transgenic silkworms ameliorates clinical signs in a Japanese macaque with mucopolysaccharidosis I., PMID:40251406
In silico approaches to identify novel anti-diabetic type 2 agents against dipeptidyl peptidase IV from isoxazole derivatives of usnic acid., PMID:40191458
Cardiovascular Risk Biomarkers in Women with and Without Polycystic Ovary Syndrome., PMID:39858399
Haploinsufficiency of lysosomal enzyme genes in Alzheimer's disease., PMID:39605615
Long-Term Health Outcomes of Individuals With Pseudodeficiency Alleles in IDUA May Inform Newborn Screening Practices for Mucopolysaccharidosis Type I., PMID:39559959
Alterations in Hurler-Scheie Syndrome Revealed by Mass Spectrometry-Based Proteomics and Phosphoproteomics Analysis., PMID:39469785
Mucopolysaccharidosis type I: founder effect of the p.P533R mutation in North Africa., PMID:39385097
Engineering memory T cells as a platform for long-term enzyme replacement therapy in lysosomal storage disorders., PMID:39367605
Circulating ECM proteins decorin and alpha-L-iduronidase differentiate ATTRwt-CM from ATTRwt-negative HFpEF/HFmrEF., PMID:39288026
Whole paternal uniparental disomy of chromosome 4 with a novel homozygous IDUA splicing variant, c.159-9T>A, in a Chinese patient with mucopolysaccharidosis type I., PMID:39132856
Programmable DNA pyrimidine base editing via engineered uracil-DNA glycosylase., PMID:39080265
Targeted proteomics involved in cardiovascular health and heart rate variability in children with overweight/obesity., PMID:38864311
Discovery of allosteric regulators with clinical potential to stabilize alpha-L-iduronidase in mucopolysaccharidosis type I., PMID:38768102
Engineering Memory T Cells as a platform for Long-Term Enzyme Replacement Therapy in Lysosomal Storage Disorders., PMID:38712248
TALEN-mediated intron editing of HSPCs enables transgene expression restricted to the myeloid lineage., PMID:38582963
Molecular docking analysis of a dermatan sulfate tetra-saccharide to human alpha-L-iduronidase., PMID:38250526
α-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1/2 trial., PMID:38204164
Co-Analysis of Serum and Urine Differentially Expressed Proteins in Mucopolysaccharidosis Type I., PMID:38164767
Leveraging diverse cell-death related signature predicts the prognosis and immunotherapy response in renal clear cell carcinoma., PMID:38146369
Generation and Characterization of Iduronidase-Cleavable ADCs., PMID:38054705
Discovery of Novel Chromenopyridine Derivatives as Readthrough-Inducing Drugs., PMID:38044139
Utilizing AAV-mediated LEAPER 2.0 for programmable RNA editing in non-human primates and nonsense mutation correction in humanized Hurler syndrome mice., PMID:37872590
Drug-induced eRF1 degradation promotes readthrough and reveals a new branch of ribosome quality control., PMID:37651229
Genetic insight into the putative causal proteins and druggable targets of osteoporosis: a large-scale proteome-wide mendelian randomization study., PMID:37448626
Identification of an α-l-iduronidase (IDUA) M1T mutation in a Chinese family with autosomal recessive mucopolysaccharidosis I., PMID:37347427
Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice., PMID:37251981
Metabolic Cardiomyopathies and Cardiac Defects in Inherited Disorders of Carbohydrate Metabolism: A Systematic Review., PMID:37239976
Identifying the genetic causes of phenotypically diagnosed Pakistani mucopolysaccharidoses patients by whole genome sequencing., PMID:37091798
A Novel IDUA Mutation Causing Ocular Disease in 2 Siblings., PMID:36951468
Biochemical Characteristics of iPSC-Derived Dopaminergic Neurons from N370S GBA Variant Carriers with and without Parkinson's Disease., PMID:36901867
Decreased Levels of Chaperones in Mucopolysaccharidoses and Their Elevation as a Putative Auxiliary Therapeutic Approach., PMID:36840025
Discovery of small-molecule protein stabilizers toward exogenous alpha-l-iduronidase to reduce the accumulated heparan sulfate in mucopolysaccharidosis type I cells., PMID:36563498
[Analysis of a child with mucopolysaccharidoses type I due to compound heterozygous variants of IDUA gene]., PMID:36184100
Identification of a novel fusion Iduronidase with improved activity in the cardiovascular system., PMID:36159322
Ataluren suppresses a premature termination codon in an MPS I-H mouse., PMID:35857082
Improving yield of a recombinant biologic in a Brassica hairy root manufacturing process., PMID:35822204
A rapid and non-invasive proteomic analysis using DBS and buccal swab for multiplexed second-tier screening of Pompe disease and Mucopolysaccharidosis type I., PMID:35787971
Liver-directed gene therapy corrects neurologic disease in a murine model of mucopolysaccharidosis type I-Hurler., PMID:35573046
Efficient in vitro and in vivo RNA editing via recruitment of endogenous ADARs using circular guide RNAs., PMID:35145312
In silico analysis of potential off-target sites to gene editing for Mucopolysaccharidosis type I using the CRISPR/Cas9 system: Implications for population-specific treatments., PMID:35073349
Drosophila D-idua Reduction Mimics Mucopolysaccharidosis Type I Disease-Related Phenotypes., PMID:35011691
Molecular characterization of a large cohort of mucopolysaccharidosis patients: Iran Mucopolysaccharidosis RE-diagnosis study (IMPRESsion)., PMID:35005816
Impaired ion homeostasis as a possible associate factor in mucopolysaccharidosis pathogenesis: transcriptomic, cellular and animal studies., PMID:34928474
Molecular analysis and novel variation identification of Chinese pedigrees with mucopolysaccharidosis using targeted next-generation sequencing., PMID:34813777
Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome., PMID:34788506
Why SNP rs3755955 is associated with human bone mineral density? A molecular and cellular study in bone cells., PMID:34783964
Which Is the Best In Silico Program for the Missense Variations in IDUA Gene? A Comparison of 33 Programs Plus a Conservation Score and Evaluation of 586 Missense Variants., PMID:34746235
Mucopolysaccharidoses type I gene therapy., PMID:34189746
For research use only. Not for human or drug use.
